RECRUITINGPhase 4INTERVENTIONAL
Correction of Psoriatic T Cell Signatures by Deucravacitinib
About This Trial
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Who May Be Eligible (Plain English)
Who May Qualify:
1. 18 years of age or older
2. Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)
Who Should NOT Join This Trial:
1. taking systemic immunosuppressives in the last 12 weeks
2. pregnancy
3. severe weakened immune system (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. 18 years of age or older
2. Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)
Exclusion Criteria:
1. taking systemic immunosuppressives in the last 12 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Treatments Being Tested
DRUG
deucravacitinib
Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
Locations (1)
University of California, San Francisco
San Francisco, California, United States